 |
Pharmacogenomic
Services
Your Source for Pharmacogenomics,
Biomarker and Mutation Discovery Research |
At TRANSGENOMIC, we bring discoveries to life. Working as an extension of your team and partner in clinical trial support, together we can help you open windows of discovery that translates into understanding disease, biomarkers and drug development providing effective therapeutics, diagnostics and healthier lives.
 |
SUPERIOR TECHNOLOGY
Featuring our WAVE® Mutation Detection System and SURVEYOR® Nuclease technology, we utilize the most advanced technology platforms available that drive accelerated drug discovery and biomarker development including: |
| |
Capillary Electrophoresis
Micro-RNA Analysis
Chromosomal Micro Array |
Gene Sequencing
Methylation Analysis
Cytogenetics |
PCR/RT-PCR
FISH
IHC |
| |
UNPARALLELED SENSITIVITY
Our expertise and technology provide mutant allele LOD (Limit of Detection) to 0.5%. |
| |
COMPREHENSIVE MUTATION COVERAGE
Whether you’re searching for Somatic or Germ-line mutations, our experience can find the mutations providing answers to your questions. |
| |
Mutations
CPG Islands
Mitochondrial Mutations |
Novel Variants
Mito-Depletions
Splice-donor Sites |
SNPs
Insertions
Deletions |
| BIOMARKER DEVELOPMENT
|
 |
ANY GENE — ANY ORGANISM — ANY SAMPLE
From whole blood to FFPEs, cell pellets to biopsies, our capabilities make it easy
to start your projects in a results-driven environment.
GENES AND DISEASE ANALYSIS
Link mutation data with treatment outcomes to aid in biomarker development. |
| ASSAY DESIGN AND VALIDATION
|
 |
CUSTOMIZED
Assays designed specifically for your projects or choose from our portfolio of hundreds of assays and genes.
FAST
Our rapid assay development and validation deliver results when you need them.
CONSULTING SERVICES
Our staff can advise you on how to customize your protocols to best meet your requirements and deliverables.
|
| PRE-CLINICAL TO
PHASE III CLINICAL TRIAL SUPPORT |
| We offer GLP and CLIA certified laboratory
services and can meet the most stringent requirements or reporting
guidelines. |
| SERVICES PROVIDED |
Early Screening
Therapeutic Toxicity
Detection of Metastatic Events |
Patient Stratification
Biomarker Discovery & Validation
Statistical Analysis |
Assessment of Drug Resistance
Disease Modeling
Pharmacogenomic Interactions |
| |
|
|
When Finding the Gene Matters
For questions or to discuss a new project,
contact our professionals at 240-631-2001.
|